Srihari Gopal Selected Research

Secondary Prevention

1/2020	Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies.
1/2019	Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia.
1/2018	Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled Study.
1/2016	Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
8/2015	Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
8/2014	Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia.
7/2013	Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies.
6/2012	Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia.
6/2010	Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Srihari Gopal Research Topics

Disease

60	Schizophrenia (Dementia Praecox) 01/2022 - 08/2009
7	Psychotic Disorders (Schizoaffective Disorder) 01/2018 - 08/2005
5	Tremor (Tremors) 01/2019 - 01/2011
4	Dyskinesias (Dyskinesia) 01/2019 - 01/2011
4	Psychomotor Agitation (Akathisia) 01/2019 - 01/2011
4	Pain (Aches) 10/2018 - 06/2010
3	Parkinsonian Disorders (Parkinsonism) 01/2019 - 09/2010
3	Hyperprolactinemia 09/2017 - 10/2012
3	Headache (Headaches) 08/2015 - 05/2011
2	Sleepiness 11/2016 - 02/2015
2	Weight Gain 11/2016 - 02/2015
2	Mania (Manias) 01/2014 - 08/2005
1	Neurodevelopmental Disorders 01/2022
1	Neuroleptic Malignant Syndrome 03/2019
1	Injection Site Reaction 10/2018
1	Orthostatic Hypotension (Postural Hypotension) 11/2016
1	Nasopharyngitis 08/2015
1	Hyperkinesis 02/2015
1	Dystonia (Limb Dystonia) 02/2015
1	Mental Disorders (Mental Disorder) 01/2014
1	Sleep Initiation and Maintenance Disorders (Insomnia) 05/2011
1	Delirium 02/2011
1	Tardive Dyskinesia 01/2011
1	Myalgia 06/2010
1	Dizziness (Lightheadedness) 06/2010
1	Bipolar Disorder (Manic Depressive Psychosis) 08/2005

Drug/Important Bio-Agent (IBA)

59	Paliperidone Palmitate FDA Link 01/2022 - 08/2009
25	Antipsychotic Agents (Antipsychotics)IBA 01/2021 - 02/2010
8	Risperidone (Risperdal Consta)FDA LinkGeneric 08/2018 - 08/2005
5	ProlactinIBA 01/2018 - 10/2012
2	Aripiprazole (Abilify)FDA Link 01/2018 - 02/2015
2	TabletsIBA 11/2016 - 08/2014
2	Cholinergic Antagonists (Anticholinergics)IBA 11/2016 - 01/2011
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2022
1	Sp4 Transcription FactorIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2021
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2018
1	Dopamine (Intropin)FDA LinkGeneric 01/2018
1	CholesterolIBA 11/2016
1	Glucose (Dextrose)FDA LinkGeneric 11/2016
1	HDL LipoproteinsIBA 11/2016
1	Olanzapine (Zyprexa)FDA Link 01/2014
1	bromperidol (Impromen)IBA 01/2011
1	fluphenazine depot (modecate)FDA LinkGeneric 01/2011
1	Haloperidol (Haldol)FDA LinkGeneric 01/2011
1	bromperidol decanoateIBA 01/2011
1	haloperidol decanoate FDA LinkGeneric 01/2011

Therapy/Procedure

31	Injections 01/2022 - 08/2009
9	Secondary Prevention 01/2020 - 06/2010
1	Aftercare (After-Treatment) 01/2018
1	Therapeutics 01/2016
1	Intramuscular Injections 09/2014